Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine dose comparison for reversal of neuromuscular blockade in children undergoing tonsillectomy
RBR-4xrx2g3Phase 4Completed
- Sponsor
- Pontifícia Universidade Católica de São Paulo
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of neostigmine in Anesthesia-related recovery impairment (ARRI) (4 arms), sponsored by Pontifícia Universidade Católica de São Paulo. Primary endpoint: Time to reversal of moderate neuromuscular blockade. Started Apr 2024; status: completed.
02
Drugs
neostigmine
03
Conditions
Anesthesia-related recovery impairment (ARRI)
Beyond the preview
Go deeper on RBR-4xrx2g3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4xrx2g3.